This company is no longer active
SESN Stock Overview
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sesen Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.58 |
| 52 Week High | US$19.30 |
| 52 Week Low | US$7.30 |
| Beta | 0.83 |
| 1 Month Change | 8.32% |
| 3 Month Change | 21.04% |
| 1 Year Change | -7.05% |
| 3 Year Change | -12.67% |
| 5 Year Change | -45.32% |
| Change since IPO | -94.20% |
Recent News & Updates
Recent updates
Sesen Bio and Carisma Therapeutics announce merger agreement
Sep 21Sesen Bio GAAP EPS of -$0.16 misses by $0.03
Aug 08Sesen Bio granted additional time period for regaining compliance
Jul 27Sesen Bio slips after decision to pause U.S. studies for lead asset
Jul 18Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
Jun 02We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully
Apr 17
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate
Dec 05Sesen Bio: Interesting Price Drop After CRL
Nov 24Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
Nov 17Sesen Bio: The Road Ahead
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00
Aug 12Sesen Bio: Binary Event Approaching
Jun 13Sesen Bio inks global supply partnership with Qilu Pharmaceutical
Jun 02Sesen Bio EPS misses by $0.27
May 10Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
May 07News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat
Feb 18Sesen announces positive FDA meeting for vicineum's marketing application
Feb 01Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
Jan 26Sesen Bio/Qilu Pharma's Vicineum IND application accepted for review in China
Jan 13Sesen Bio files US application for its Vicineum in bladder cancer
Dec 21Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook
Dec 21
Sesen Bio: A Look At Vicineum's Potential
Nov 29Sesen Bio, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 09Shareholder Returns
| SESN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.5% | -4.7% | -3.7% |
| 1Y | -7.1% | -2.7% | 20.2% |
Return vs Industry: SESN underperformed the US Biotechs industry which returned 4.3% over the past year.
Return vs Market: SESN exceeded the US Market which returned -8.5% over the past year.
Price Volatility
| SESN volatility | |
|---|---|
| SESN Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SESN has not had significant price volatility in the past 3 months.
Volatility Over Time: SESN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 17 | Thomas Cannell | sesenbio.com |
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent.
Sesen Bio, Inc. Fundamentals Summary
| SESN fundamental statistics | |
|---|---|
| Market cap | US$2.56b |
| Earnings (TTM) | -US$19.88m |
| Revenue (TTM) | US$40.00m |
64.0x
P/S Ratio-128.7x
P/E RatioIs SESN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SESN income statement (TTM) | |
|---|---|
| Revenue | US$40.00m |
| Cost of Revenue | US$1.99m |
| Gross Profit | US$38.02m |
| Other Expenses | US$57.90m |
| Earnings | -US$19.88m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.098 |
| Gross Margin | 95.04% |
| Net Profit Margin | -49.71% |
| Debt/Equity Ratio | 0% |
How did SESN perform over the long term?
See historical performance and comparison